Medications for the Treatment of Diabetes
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Endocrinology and Metabolism Research".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 107
Special Issue Editor
Interests: genetic risk score; differentially expressed genes; data mining and analysis; machine learning; artificial intelligence; epidemiology; biostatistics; bioinformatics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Diabetes is a chronic disease that develops when the pancreas cannot produce enough insulin, or when the body cannot effectively use that insulin well. To our knowledge, diabetes can be divided into type 1 and type 2. Insulin medication is the most common treatment for type 1 diabetes. However, if individuals have type 2 diabetes their body can still make insulin but can no longer use it well. Most medications for type 2 diabetes are oral drugs, such as insulin, Biguanides, Dopamine-2 agonist, Dipeptidyl peptidase-4 (DPP-4) inhibitors, Glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists), Meglitinides, Sodium-glucose transporter (SGLT) 2 inhibitors, Sulfonylureas, and Thiazolidinediones. To date, a high prevalence of diabetes has been found in developed countries, and the risk factors for diabetes have been identified as age, sex, body mass index, smoking status, and comorbidities, including peripheral vascular disease and hypertension. Some medications for diabetes may highten the patient’s risk of developing other diseases. Particularly, dementia can also occur after a person has lived with diabetes for many years. Thus, new questions are emerging that need to be answered. The aim of this Special Issue is to understand the state of the art and the latest advances in the medications and treatment of diabetes, and how we may further improve the prognosis of diabetes.
Dr. I-Shiang Tzeng
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- diabetes
- insulin
- oral drugs
- Biguanides
- medications
- antidiabetic drugs
